Skip to content

A Randomized Controlled Study of Prolonging the Time of Progesterone Supplementation to Improve the Pregnancy Outcome of Single Day 6 Blastocyst Transfer of Freeze-thaw Cycle

A Randomized Controlled Study of Prolonging the Time of Progesterone Supplementation to Improve the Pregnancy Outcome of Single Day 6 Blastocyst Transfer of Freeze-thaw Cycle

Status
UNKNOWN
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04938011
Enrollment
900
Registered
2021-06-24
Start date
2021-07-31
Completion date
2024-06-30
Last updated
2021-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility

Brief summary

This is a single-center, prospective, randomized controlled study. Patients with single blastocyst transfer in the freeze-thaw cycle, aged from 20 to 38 years, with less than three transfers, and with HRT-cycle single D6 blastocyst transfer in the current cycle were enrolled as the study participants. They were randomized into two groups using an Excel table, and the efficacy was evaluated in a blinded manner by a third party who was unaware of the grouping; the data summary phase was performed by blinded statistical analysis with triple separation of the investigator, operator, and statistician.

Interventions

DRUGprogesterone

the transfer of day 6 blastocyst on the 6th day of progesterone supplementation

Sponsors

Nanjing University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
20 Years to 38 Years
Healthy volunteers
No

Inclusion criteria

1. Aged 20 to 38 years. 2. Less than three transfers. 3. Undergoing HRT freeze-thaw cycle single blastocyst transfer in the current cycle. 4. Having consented to participate in this study and signed the informed consent form.

Exclusion criteria

1. Chromosomal abnormality in either the patient or their partner 2. Contraindications to hormone replacement therapy. 3. Patients with intramural myoma affecting the morphology of the uterine cavity, severe adenomyosis, endometriosis, congenital uterine anomalies, endometrial tuberculosis, intrauterine adhesion and other diseases significantly affecting embryonic implantation. 4. Currently participating in another clinical study.

Design outcomes

Primary

MeasureTime frame
Embryo implantation rate30 days after embryo transplantation

Countries

China

Contacts

Primary ContactYue Jiang, PhD
jiangyue85@163.com025-83106666

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 12, 2026